Clinical Trial Update: BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension [Phase 3]

View source ↗

Summary

Phase 3 long-term extension study of BAY63-2521 in patients with pulmonary arterial hypertension has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension Pulmonary
• Pulmonary Arterial Hypertension

Drugs mentioned

• BAY63-2521

Snippet

Sponsor: Bayer | Conditions: Hypertension, Pulmonary | Phase 3 | Status: COMPLETED | Results posted: 2020-10-22